Zynerba Pharmaceuticals, Inc. (ZYNE) Social Stream
ZYNERBA PHARMACEUTICALS INC (ZYNE) Price Targets From Analysts
Use the tables below to see what analysts covering ZYNERBA PHARMACEUTICALS INC think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-18 | 5 | $9 | $4.5 | $7.35 | $1.3 | 465.38% |
| 2022-01-06 | 5 | $9 | $3.5 | $7.15 | $1.3 | 450% |
| 2022-01-20 | 4 | $9 | $3.5 | $6.625 | $1.3 | 409.62% |
| 2022-05-17 | 4 | $9 | $2.75 | $6.437 | $1.3 | 395.15% |
| 2022-06-13 | 4 | $9 | $1 | $6 | $1.3 | 361.54% |
| 2022-08-11 | 5 | $11 | $6 | $8.6 | $1.3 | 561.54% |
| 2022-08-17 | 5 | $11 | $1 | $7 | $1.3 | 438.46% |
| 2022-11-01 | 5 | $11 | $1 | $6.8 | $1.3 | 423.08% |
| 2022-11-18 | 5 | $11 | $0.76 | $6.752 | $1.3 | 419.38% |
| 2022-12-22 | 5 | $11 | $0.76 | $5.952 | $1.3 | 357.85% |
| 2023-03-29 | 4 | $11 | $0.5 | $5.9 | $1.3 | 353.85% |
| 2023-03-31 | 5 | $11 | $0.5 | $5.9 | $1.3 | 353.85% |
| 2023-05-17 | 3 | $10 | $0.4 | $6.35 | $1.3 | 388.46% |
| 2023-05-18 | 5 | $10 | $0.4 | $5.68 | $1.3 | 336.92% |
| 2023-08-14 | 4 | $10 | $1.4 | $5.7 | $1.3 | 338.46% |
| 2023-08-16 | 4 | $1.4 | $1.11 | $1.255 | $1.3 | -3.46% |
The Trend in the Analyst Price Target
ZYNE's average price target has moved down $6 over the prior 30 months.
ZYNE reports an average of 1,264.66% for its upside potential over the past 41 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-11-15 | 5 | 11.0 | 0.76 | 6.752 | 0.64 | 955% |
| 2023-03-31 | 5 | 11.0 | 0.50 | 5.900 | 0.43 | 1272.09% |
| 2023-05-17 | 3 | 11.0 | 0.40 | 5.880 | 0.33 | 1681.82% |
| 2023-05-17 | 3 | 10.0 | 0.40 | 6.350 | 0.33 | 1824.24% |
| 2023-08-16 | 4 | 1.4 | 1.11 | 1.255 | 1.29 | -2.71% |
ZYNE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 3 | 0 | 0 | 4 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
Over the past 23 months, ZYNE's average broker recommendation rating worsened by 1.6.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- ZYNERBA PHARMACEUTICALS INC's average analyst price target is greater than 119.61% of all US stocks.
- In terms of how ZYNERBA PHARMACEUTICALS INC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is higher than 1830.08% of that group.
- To contextualize these metrics, consider that out of all US stocks, ZYNERBA PHARMACEUTICALS INC's variance in analysts' estimates is lower than -1742.23% of them.
- To contextualize these metrics, consider that out of stocks in the micro market cap category, ZYNERBA PHARMACEUTICALS INC's number of analysts covering the stock is greater than 1711.44% of them.
Stocks similar to ZYNERBA PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are JAGX, ACST, and VBLT.
View All Top Stocks by Price Target
Is ZYNE a Buy, Hold or Sell? See the POWR Ratings now!